Friday 20 March 2026
Internal Reference Number: FOI_9213
Date Request Received: 10/02/2026 00:00:00
Date Request Replied To: 27/02/2026 00:00:00
This response was sent via: By Email
Request Summary: Treatment of Mantle Cell Lymphoma (MCL)
Request Category: Companies
| Question Number 1: How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to? | |
| Answer To Question 1: Please see our response to Q1-3 in the attached spreadsheet. To accompany this answer to question 1 please also see the documents listed below:  13523 - FOI_9213 - Treatment of Mantle Cell Lymphoma (MCL).xlsx | |
| Question Number 2: How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments: • BR (Bendamustine + rituximab) • VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) • R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) • R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) • CVP (cyclophosphamide, vincristine and prednisolone) • Brukinsa (zanubrutinib) • Imbruvica (ibrutinib) • Velcade (bortezomib) + chemotherapy • Tecartus (brexucabtegene autoleucel) • R-BAC (rituximab, bendamustine and cytarabine) • R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) • Any other systemic anti-cancer therapy • Wait and watch (monitoring only, no active treatment) | |
| Answer To Question 2: Please see our response to Q1-3 in the attached spreadsheet. | |
| Question Number 3: How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments: For this question, please only count patients that have received the below treatments for the first time. • BR (Bendamustine + rituximab) • VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) • R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) • R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) • CVP (cyclophosphamide, vincristine and prednisolone) • Brukinsa (zanubrutinib) • Imbruvica (ibrutinib) • Velcade (bortezomib) + chemotherapy • Tecartus (CAR-T) • R-BAC (rituximab, bendamustine and cytarabine) • R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) • Any other systemic anti-cancer therapy • Wait and watch (monitoring only, no active treatment) | |
| Answer To Question 3: Please see our response to Q1-3 in the attached spreadsheet. | |
| Question Number 4: If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials. | |
| Answer To Question 4: The Trust is currently participating in one ongoing clinical trial for the treatment of MCL: ENRICH Ibrutinib for untreated mantle cell lymphoma IRAS number 180518, ISRCTN 11038174 | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
